These data indicate that sustained DNA methyltransferase 1 inhibition with frequent lower doses of HMA may offer a strategy to overcome VEN resistance, especially in the difficult-to-treat TP53-mutated AML. Here, DNMT1 is linked to acute myeloid leukemia.